Evidence map›Paper›PMID 25552899›Full record

ReviewDrug design, development and therapy2015

An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides.

Jiang Cheng, Zhi-Wei Zhou, Hui-Ping Sheng, Lan-Jie He, Xue-Wen Fan, Zhi-Xu He, Tao Sun, Xueji Zhang, Ruan Jin Zhao, Ling Gu and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 3 pooled it
14.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 3 syntheses or guidelines pooled it, 211 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Structural-activity relationship ofFrontiers in immunology · 2026
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Therapeutic potential ofFrontiers in nutrition · 2025
    Review
  13. Frontiers in nutrition · 2025
    Article
  14. Article
  15. Article
  16. Heliyon · 2024
    Article
  17. Article
  18. Effects ofFrontiers in immunology · 2024
    Article
  19. Article
  20. Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Jiang ChengDepartment of Neurology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, People's Republic of China ; Department of Pharmaceutical Science, College of Pharmacy, University of South Florida, Tampa, FL, USA.
Zhi-Wei ZhouDepartment of Pharmaceutical Science, College of Pharmacy, University of South Florida, Tampa, FL, USA.
Hui-Ping ShengDepartment of Infectious Diseases, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, People's Republic of China.
Lan-Jie HeDepartment of Endocrinology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, People's Republic of China.
Xue-Wen FanDepartment of Neurology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, People's Republic of China.
Zhi-Xu HeGuizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center and Sino-US Joint Laboratory for Medical Sciences, Guiyang Medical University, Guiyang, Guizhou, People's Republic of China.
Tao SunKey Laboratory of Craniocerebral Diseases of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan, Ningxia, People's Republic of China.
Xueji ZhangResearch Center for Bioengineering and Sensing Technology, University of Science and Technology Beijing, Beijing, People's Republic of China.
Ruan Jin ZhaoCenter for Traditional Chinese Medicine, Sarasota, FL, USA.
Ling GuSchool of Biology and Chemistry, University of Pu'er, Pu'er, Yunnan, People's Republic of China.
Chuanhai CaoDepartment of Pharmaceutical Science, College of Pharmacy, University of South Florida, Tampa, FL, USA.
Shu-Feng ZhouDepartment of Pharmaceutical Science, College of Pharmacy, University of South Florida, Tampa, FL, USA ; Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center and Sino-US Joint Laboratory for Medical Sciences, Guiyang Medical University, Guiyang, Guizhou, People's Republic of China.
University of South Florida · USGuiyang Medical University · CNNingxia Medical University · CNPuer University · CNUniversity of Science and Technology Beijing · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lycium barbarum berries, also named wolfberry, Fructus lycii, and Goji berries, have been used in the People's Republic of China and other Asian countries for more than 2,000 years as a traditional medicinal herb and food supplement. L. barbarum polysaccharides (LBPs) are the primary active components of L. barbarum berries and have been reported to possess a wide array of pharmacological activities. Herein, we update our knowledge on the main pharmacological activities and possible molecular targets of LBPs. Several clinical studies in healthy subjects show that consumption of wolfberry juice improves general wellbeing and immune functions. LBPs are reported to have antioxidative and antiaging properties in different models. LBPs show antitumor activities against various types of cancer cells and inhibit tumor growth in nude mice through induction of apoptosis and cell cycle arrest. LBPs may potentiate the efficacy of lymphokine activated killer/interleukin-2 combination therapy in cancer patients. LBPs exhibit significant hypoglycemic effects and insulin-sensitizing activity by increasing glucose metabolism and insulin secretion and promoting pancreatic β-cell proliferation. They protect retinal ganglion cells in experimental models of glaucoma. LBPs protect the liver from injuries due to exposure to toxic chemicals or other insults. They also show potent immunoenhancing activities in vitro and in vivo. Furthermore, LBPs protect against neuronal injury and loss induced by β-amyloid peptide, glutamate excitotoxicity, ischemic/reperfusion, and other neurotoxic insults. LBPs ameliorate the symptoms of mice with Alzheimer's disease and enhance neurogenesis in the hippocampus and subventricular zone, improving learning and memory abilities. They reduce irradiation- or chemotherapy-induced organ toxicities. LBPs are beneficial to male reproduction by increasing the quality, quantity, and motility of sperm, improving sexual performance, and protecting the testis against toxic insults. Moreover, LBPs exhibit hypolipidemic, cardioprotective, antiviral, and antiinflammatory activities. There is increasing evidence from preclinical and clinical studies supporting the therapeutic and health-promoting effects of LBPs, but further mechanistic and clinical studies are warranted to establish the dose-response relationships and safety profiles of LBPs.

Indexed as

AnimalsAntineoplastic Agents, PhytogenicAntioxidantsApoptosisBlood GlucoseCell ProliferationHumansHypoglycemic AgentsLyciumPolysaccharidesSubstrate SpecificityAntineoplastic Agents, PhytogenicAntioxidantsBlood GlucoseHypoglycemic AgentsPolysaccharidesanti-agingantioxidantapoptosiscancerchemotherapyischemic/reperfusion injurymechanismnatural killerT cell

Identifiers

PMID25552899
PMCPMC4277126
OpenAlexW2066993488

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.